Your LFT Came Back Abnormal: What Your Doctor Orders Next

Before a single new test: the questions your doctor will ask

Follow-up testing doesn't actually start with a test. It starts with a conversation, and the quality of that conversation shapes everything after it. There is a reason liver specialists spend the first ten minutes of a follow-up visit asking questions that sound unrelated to your blood report.

Alcohol comes first, and it comes with specifics. Not "do you drink," but how much, how often, for how many years, and when you last drank. Some clinics use a short standardized questionnaire for this. The point isn't moral judgment; it's arithmetic. The liver processes a fairly fixed amount of alcohol per hour, and the cumulative load is what matters. Patients routinely understate by half, and doctors know it, which is why the question gets asked twice in different ways.

Medicines and supplements come second, and this is where patients can genuinely help. Bring the strip, the bottle, the box, whatever you have. Herbal and ayurvedic preparations deserve special mention here because they carry an aura of safety that the liver doesn't share; several well-documented cases of severe liver injury trace back to "natural" products. Bodybuilding supplements, weight-loss teas, and multi-ingredient "liver detox" products are repeat offenders. If you started anything new in the three months before the abnormal test, say so, even if it feels embarrassing. Your doctor has heard it all before, and this one detail can save you five other tests.

Then come the metabolic questions: weight changes, diabetes, blood pressure, cholesterol, because fatty liver travels with the metabolic syndrome and the follow-up plan for it looks different from the plan for, say, a suspected autoimmune problem. Family history matters too, liver disease, yes, but also diabetes and thyroid problems, which cluster with autoimmune conditions. And finally the infection-risk questions: blood transfusions, tattoos or piercings done outside sterile settings, injectable drug use, unprotected sex, travel to regions where hepatitis is common. Nobody enjoys answering these. Answer them anyway. Each "yes" redirects the follow-up testing toward the right target and each honest "no" lets your doctor cross a whole category off the list.

The repeat blood draw, done smarter

When the repeat happens, it usually isn't just the LFT panel again. The repeat draw gets smarter. A complete blood count with differential often comes along, because low platelets or anemia can hint at chronic liver disease or portal hypertension, things a single LFT panel would never show. The comprehensive metabolic panel adds kidney function, electrolytes, and glucose to the picture. None of this is random ordering. It is your doctor building a wider frame around the original flag so the next round of tests doesn't start from scratch.

One more blood test sometimes sneaks into this round, and it confuses people: creatine kinase, or CK. It gets ordered when AST is the dominant elevation, because AST isn't exclusive to the liver. Strenuous exercise, a muscle injury, even a statin-related muscle ache can push AST up while the liver is perfectly fine. CK tells the two apart. If CK is high, the "liver problem" may actually be a muscle problem, and the whole follow-up path changes. We've seen this exact scenario at the lab: a young man with an AST twice the limit, a normal ALT, and a CK through the roof after starting a new gym routine. No liver disease at all.

If the abnormality persists past this point, or if it was marked from the start, the targeted follow-up tests begin. Here is what each one is actually hunting for.

The ultrasound: the first and usually only scan you need

Almost every follow-up path includes an abdominal ultrasound, and it is the single most useful next step for the money. It takes about fifteen minutes, involves no needles and no contrast dye, just cool gel and a probe gliding over your belly, and it answers several questions at once: is the liver fatty, is there a gallstone blocking a bile duct, are the ducts dilated, is there a lump that shouldn't be there, are there signs of portal hypertension like an enlarged spleen?

Ultrasound is remarkably good at spotting moderate to severe fatty change, which matters because fatty liver is now the most common cause of abnormal LFTs in India and worldwide. It is also the test that separates inside-the-liver problems from outside-the-liver ones. If the bile ducts are dilated, the problem is likely downstream, a stone or a stricture, and the next step becomes a different kind of scan (an MRCP, which maps the bile ducts in detail). If the ducts are normal, the search stays inside the liver itself.

We see a lot of ultrasound requests paired with repeat LFTs at our lab in Malad, and patients are usually relieved at how anticlimactic the scan is after the anxiety the blood report caused.

Hepatitis B and C: ruling out the infections with answers

If there is one follow-up your doctor will not skip, it is screening for hepatitis B and hepatitis C. The HBsAg test checks for an active hepatitis B infection, and the anti-HCV test screens for hepatitis C exposure, usually with a confirmatory PCR test if it comes back positive.

The reason these top the list is simple and hopeful: both are treatable now, and both can damage the liver for twenty years without a single symptom. Chronic hepatitis C, in particular, went from a lifelong sentence to a curable infection with a course of tablets. Finding it on the back of an abnormal LFT is one of the genuinely good outcomes of follow-up testing.

If one of these screens comes back positive, the follow-up gets a follow-up. For hepatitis B, that usually means checking whether the infection is active (a viral DNA level), whether the liver is inflamed right now, and whether family members need screening and vaccination. For hepatitis C, a positive antibody test is always confirmed with a viral RNA test, because about a quarter of people clear the virus on their own and never need treatment. Those who do need treatment then get a fibrosis assessment, often the same FIB-4 score and stiffness scan described later in this article, to decide how urgently treatment should start. None of this is an emergency in the midnight-hospital sense, but it is the kind of thing you schedule within weeks, not months.

If you've never been screened and your LFT is abnormal, expect these two. Our longer hepatitis B testing guide walks through what each marker on that panel means.

Questions patients actually ask, answered plainly

My LFT was slightly abnormal but I feel completely fine. Can I just ignore it? Not quite. About a third of mild elevations normalize on their own, but the rest don't, and feeling fine says nothing either way, since most chronic liver conditions are silent for years. Get the recheck, then decide with your doctor.

How soon should I repeat the test? For mild elevations, two to four weeks. For marked elevations, days, not weeks, and your doctor will likely start the cause-hunting tests at the same time.

Does an abnormal LFT mean my liver is failing? No. High enzymes mean liver cells are irritated; they say nothing about whether the liver is doing its job. The job markers are albumin, bilirubin, and clotting. When those are normal, the liver is coping.

I drank at a wedding last weekend. Could that be it? Honestly, yes. Alcohol is one of the few causes where a repeat test alone is genuinely justified, because the enzymes usually settle within weeks of stopping. This is also why doctors ask about drinking so directly. The number is more useful when the history is honest.

Do I need to fast for the follow-up blood tests? At our lab, yes: 9 to 12 hours of fasting for the repeat liver panel and the metabolic follow-ups, since several of them travel with lipid and glucose markers that need a fasting sample. Water is fine; morning black tea without milk or sugar is usually acceptable, but ask when you book.

Can regular medicines raise my LFTs, even at normal doses? They can. Cholesterol medicines, TB medicines, some antibiotics, anti-seizure drugs, herbal and ayurvedic preparations, and bodybuilding supplements all appear on the suspect list. This is why the medicines-and-supplements question comes before almost every other follow-up.

Why check hepatitis if I've never been jaundiced or sick? Because chronic hepatitis B and C rarely announce themselves. Decades of quiet liver damage can precede the first symptom, and both are now manageable or curable. Screening after an abnormal LFT catches what symptoms missed.

Will the ultrasound hurt, and does it need any preparation? No, and mostly no. It is sound waves, not radiation, no needles, no contrast. You may be asked to come with a moderately full bladder or after fasting, depending on what else is being scanned, but the liver views themselves are quick and painless.

If all the follow-up tests come back normal, are we done? Mostly, yes, with one caveat. Fatty liver and early fibrosis can exist with perfectly normal enzymes, so if you carry metabolic risk factors (diabetes, obesity, high triglycerides), your doctor may still calculate a fibrosis risk score and set a recheck schedule rather than closing the file.

The autoimmune panel: when the immune system is the suspect

Autoimmune hepatitis and the autoimmune bile-duct diseases are uncommon, but they are also highly treatable with the right medicines, so missing them is costly. The follow-up blood tests for this corner are the ANA (antinuclear antibody) test, the anti-smooth muscle antibody test, the anti-mitochondrial antibody test, and a measurement of serum immunoglobulins, particularly IgG.

Each one points in a slightly different direction. A high IgG with positive ANA or anti-smooth muscle antibody raises the question of autoimmune hepatitis. A positive anti-mitochondrial antibody with a cholestatic pattern points toward primary biliary cholangitis. These are not tests your doctor orders casually; they enter the picture when the pattern fits, when other causes have come up empty, or when the abnormality has persisted for months. We offer the ANA test at the lab, and it is one of those tests where a positive result needs a specialist's interpretation, not a search engine's.

Iron, copper and alpha-1: ruling out the inherited causes

This is the part of the follow-up that surprises people most, because it has nothing to do with alcohol or viruses. Three inherited conditions can raise liver enzymes, and all three have specific blood tests.

The first is iron overload, or hemochromatosis. The screening pair is the serum ferritin test plus transferrin saturation, drawn at the same time. Ferritin alone can mislead, since it also rises with inflammation, so doctors read the two together. High ferritin with high saturation points toward true iron overload, which is manageable once found.

The second is Wilson's disease, where the body can't clear copper properly. The screening test measures ceruloplasmin, the protein that carries copper in blood. It is mainly considered in younger patients, typically under forty, because Wilson's shows up early, and a low ceruloplasmin with the right clinical picture is one of the few lab findings that points almost directly at a single diagnosis. Catch it early and the treatment, which simply helps the body get rid of copper, can prevent the liver damage entirely. The third is alpha-1 antitrypsin deficiency, a protein problem that can damage both lungs and liver; the test simply measures the protein's level in blood. It is rare enough that many labs don't run it in-house, which is why your doctor may send the sample to a reference lab and the result takes a few extra days. (Search our test list for it here.)

Coeliac disease screening sometimes joins this group too, since gluten sensitivity can cause a mild, reversible transaminase rise that settles on a gluten-free diet. It sounds unrelated until you see it happen.

FIB-4 and the stiffness scan: estimating scarring without a biopsy

One of the most useful follow-ups doesn't require a new blood draw at all. The FIB-4 score is calculated from four things already on your reports: your age, your AST, your ALT, and your platelet count. It estimates the likelihood of advanced liver scarring, and international guidance now positions it as the first fibrosis check for people with fatty liver or metabolic risk.

The bands are straightforward. Below 1.3, advanced fibrosis is unlikely, and the score is good at ruling it out. Between 1.3 and 2.67 is the grey zone, where doctors usually order a second check. Above 2.67, advanced fibrosis is likely enough to warrant a liver specialist's input. One adjustment worth knowing: after age 65, the low-risk cutoff moves to 2.0, because age is baked into the formula. Another worth knowing: FIB-4 is at its least reliable under age 35, where even significant disease can hide behind a reassuring number. FIB-4 estimates risk; it doesn't diagnose. But it decides, cheaply and instantly, who needs the next level of testing.

That next level is usually a liver stiffness scan, an elastography, which measures how stiff the liver is with a painless probe on the skin. Stiff means scarred. It is the standard second step after an indeterminate or high FIB-4, and it has quietly replaced a large number of liver biopsies. International guidance now recommends using the blood score and the scan together rather than either alone: the combination is more accurate than either test by itself, and the sequential approach has cut the number of biopsies needed by roughly a third in published studies.

When a liver biopsy enters the conversation

Biopsy is the last resort, not the next step, and it comes up in specific situations: transaminases more than five times the limit, an abnormality that persists beyond six months with every blood test negative and no fatty-liver risk factors to explain it, or evidence of advanced disease on imaging. A large study of patients with unexplained persistent abnormalities found fatty liver in about two-thirds, and the biopsy changed management in nearly one in five. So it earns its place, but only after the blood work and scans have had their say. If your doctor mentions it, ask what question the biopsy would answer that the other tests couldn't. There should be a crisp answer.

Before your follow-up draw: what actually matters

A few practical points, learned from watching thousands of follow-up draws go smoothly or not.

Medicines and supplements

Do: make a complete list of everything you take, prescription drugs, over-the-counter tablets, protein powders, herbal and ayurvedic preparations, the lot, and carry it to the appointment. The single most useful thing you can hand your doctor is an honest inventory, because several common products raise liver enzymes and stopping the culprit is sometimes the entire treatment.

Don't: stop a prescribed medicine on your own before the draw to "get a clean result." That can be dangerous with drugs like anti-seizure or TB medicines, and it also hides the very information your doctor needs. Report what you take; let the doctor decide what pauses.

Alcohol, honestly

Do: tell the truth about quantity and timing, including the wedding last weekend. Doctors aren't judging; they're calibrating. A transient alcohol bump and a chronic pattern lead to completely different follow-up plans, and the blood tests alone can't always tell them apart.

Don't: assume "just beer" or "only on weekends" doesn't count. The liver keeps its own accounts, and underreporting is the most common reason follow-up testing goes in circles.

Timing and fasting

Do: fast 9 to 12 hours before the repeat and metabolic follow-up draws, book a morning slot, and drink water normally. A morning draw also keeps the timing consistent with your original test, which makes the trend comparison honest.

Don't: squeeze in a heavy workout the evening before, or schedule the draw right after a night shift or a bout of flu. Muscle injury and acute illness both nudge transaminases up and can turn a clean recheck into a confusing one.

One small human detail about the draw itself, since people ask: the needle prick stings for about two seconds, then it's just pressure. The phlebotomist tapes a small cotton ball to your arm afterward; keep it pressed for a few minutes rather than bending your elbow into it, which is how bruises happen. At a home visit, they'll usually ask you to sit near a window or a bright spot, because good light is how veins get found on the first try. We do free home collection across Malad, Kandivali, Borivali and Goregaon, the lab runs 24x7, and reports for these follow-ups are typically ready within about 24 hours. Bookings are on 84250 40353.

Where this leaves you

Six things to carry out of this. One, a single abnormal LFT is a signal, not a diagnosis, and roughly a third of mild ones normalize on recheck. Two, the size of the elevation sets the pace: mild gets a recheck in two to four weeks, marked gets a full workup within days. Three, the pattern on your report, which enzymes are up and in what ratio, decides which follow-up tests your doctor orders. Four, the core follow-ups are a smarter repeat panel with a blood count, hepatitis B and C screening, an abdominal ultrasound, autoimmune markers, and iron studies. Five, a FIB-4 score calculated from numbers you already have estimates scarring risk and decides who needs a stiffness scan. Six, the serum bilirubin test deserves its own mention here: when bilirubin climbs alongside the enzymes, the timeline compresses from weeks to days, so a rising yellow number is the one flag to act on promptly.

If your original report is sitting on the table right now, start with the pattern, not the panic. The follow-up tests exist precisely because one abnormal number is never the whole story, and each one you complete narrows the story down. That is the entire point of the sequence: from a flag, to a pattern, to a cause, to a plan.

References

• American Association for the Study of Liver Diseases (AASLD): practice guidance on the evaluation of abnormal liver tests and on noninvasive assessment of liver fibrosis
• American College of Gastroenterology (ACG): guidance on repeat testing and evaluation of mild liver enzyme elevations
• Mayo Clinic: clinical approach to the patient with abnormal liver test results (Mayo Clinic Proceedings)
• European Association for the Study of the Liver (EASL): guidance on liver test evaluation and fibrosis risk stratification